Table 4 Recommendations for initial... | American Society of Hematology

Table 4

Recommendations for initial management of the 3 main types of CBCL

Disease type and extent	First-line therapy	Alternative therapies
PCMZL
Solitary/localized	Local radiotherapy	IFN-α i.l.
	Excision	Rituximab i.l.
	Antibiotics*	i.l. steroids
Multifocal	Wait-and-see	IFN-α i.l.
	Local radiotherapy	Rituximab i.l.
	Chlorambucil†	Topical or i.l. steroids
	Rituximab i.v.
	Antibiotics*
PCFCL
Solitary/localized	Local radiotherapy	IFN-α i.l.
	Excision	Rituximab i.l.
Multifocal	Wait-and-see	R-CVP/CHOP‡
	Local radiotherapy
	Rituximab i.v.
PCLBCL, LT
Solitary/localized	R-CHOP ± IFRT	Local radiotherapy
		Rituximab i.v.
Multifocal	R-CHOP	Rituximab i.v.

Disease type and extent	First-line therapy	Alternative therapies
PCMZL
Solitary/localized	Local radiotherapy	IFN-α i.l.
	Excision	Rituximab i.l.
	Antibiotics*	i.l. steroids
Multifocal	Wait-and-see	IFN-α i.l.
	Local radiotherapy	Rituximab i.l.
	Chlorambucil†	Topical or i.l. steroids
	Rituximab i.v.
	Antibiotics*
PCFCL
Solitary/localized	Local radiotherapy	IFN-α i.l.
	Excision	Rituximab i.l.
Multifocal	Wait-and-see	R-CVP/CHOP‡
	Local radiotherapy
	Rituximab i.v.
PCLBCL, LT
Solitary/localized	R-CHOP ± IFRT	Local radiotherapy
		Rituximab i.v.
Multifocal	R-CHOP	Rituximab i.v.

IFRT indicates involved field radiotherapy; i.l., intralesional; and i.v., intravenous.

In case of evidence for B burgdorferi infection.

Or other single or combination regimens appropriate for low-grade B-cell lymphomas.

In exceptional cases or for patients developing extracutaneous disease.